A Metastatic Cervical Adenocarcinoma Patient Carrying HER2 G292R Achieved Complete Response Upon Pyrotinib Treatment.

Abstract

Cervical cancer patients who develop distant metastasis are rarely curable with very limited treatment options. Chemotherapy is often administered but with limited efficacy. Immunotherapy and anti-angiogenesis therapy are recommended for selected cases of recurrent or metastatic cervical cancers. The clinical efficacy of inhibitors targeting HER2, a commonly mutated gene in cervical cancer, has not been elucidated. Herein, we report a metastatic cervical adenocarcinoma patient carrying HER2 G292R who benefited from pyrotinib after progression on radio-chemotherapy, achieving complete response (CR) with a progression-free survival of 25 months and counting. Our study sheds light on the treatment options for previously treated metastatic cervical adenocarcinoma patients harboring activating HER2 mutations.

• Authors: Jing Liu, Yanhong Zhuo, Feng Wang, Zirong Li, Yibin Lin, Li Li, Junping Pan, Yanwen Song, Haiwei Du, Chanhe Li, Qin Xu
• Journal: OncoTargets and therapy (Onco Targets Ther) Vol. 14 Pg. 4833-4836 ( 2021) ISSN: 1178-6930 [Print] New Zealand
• PMID: 34556997 (Publication Type: Case Reports)
• Copyright: © 2021 Liu et al.